Study of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance in Adults

What this Trial Is About

Researchers are studying Clonal Hematopoiesis of Indeterminate Potential CHIP and Clonal Cytopenia of Undetermined Significance CCUS, which involve changes in a persons DNA that may increase the risk of blood cancers and cardiovascular disease. These conditions mostly affect older adults, and this research aims to understand how CHIP and CCUS progress over time and to verify associations with diseases such as blood cancers and atherosclerosis. The study also seeks to identify new potential clinical links. Participants will be screened through gene testing using blood samples and enrolled after passing initial screenings that include physical exams and medical history reviews. Those with CCUS may have a bone marrow sample taken. Eligible participants will undergo various tests including blood and urine samples, heart monitoring, ultrasound of neck arteries, liver and heart scans, bone density scans, lung function tests, and cheek swabs or skin biopsies. Advanced heart and full-body scans are optional. Participants will be followed up yearly for 10 years, repeating tests every one to three years depending on the procedure. Throughout the study, participants will be involved in regular assessments to monitor their condition, including immune response and mutation stability. Researchers will measure associations with various health factors such as infections, metabolic conditions, and organ health. The study includes long-term follow-up visits over a decade to track disease progression and other clinical outcomes. This comprehensive monitoring helps to deepen understanding of CHIP and CCUS and their impacts on health.

CHIP/CCUS Natural History Protocol